The 2025 ACC scientific statement on obesity in heart failure addresses the therapeutic role of GLP‐1 and dual GIP/GLP‐1 agonists for patients with HFpEF and obesity, and it recommends multidisciplinary care pathways to integrate anti‐obesity medications safely and effectively [43]. The gene discussed is GIP; the disease is heart failure.